Research programme: hepatitis C virus polymerase inhibitors - B&C Pharma/XTL
Alternative Names: BC 2329; HCV-SMLatest Information Update: 11 Jul 2007
Price :
$50 *
At a glance
- Originator B&C Pharma
- Class Small molecules
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 28 Dec 2005 This programme is still in active development
- 19 Jan 2004 Data presented at the Frontiers in drug development for Viral Hepatitis - Hep DART 2003 (Hep DART-2003) have been added to the adverse events, pharmacokinetics and pharmacodynamics sections
- 07 Jul 2003 A potential drug candidate, HepeXTM-C SM1, has been identified for further development